Clinical Trial Update: TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases [Phase 2]

View source ↗

Summary

TYK Medicines is conducting a Phase 2 trial of TY-9591 for patients with EGFR-mutant non-small cell lung cancer, including those with brain metastases, and the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TY-9591 (TY-9591)

Snippet

Sponsor: TYK Medicines, Inc | Conditions: NSCLC, EGFR Activating Mutation | Phase 2 | Status: RECRUITING